Skip to content

GHRP-2 Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

GHRP-2 is generally well-tolerated in clinical studies, with the intact somatostatin feedback loop providing a natural safety mechanism against GH overproduction.

Common (typically mild and transient):

  • Increased appetite (moderate, less than GHRP-6)
  • Flushing and warmth at the injection site or face
  • Transient drowsiness or sleepiness, particularly with evening doses
  • Mild water retention and peripheral edema
  • Increased gastrointestinal motility

Less Common:

  • Elevations in cortisol and ACTH (moderate, comparable to hCRH)
  • Mild prolactin elevation (less than TRH-induced levels)
  • Numbness or tingling in extremities
  • Joint stiffness
  • Lightheadedness post-injection

Rare or Theoretical Concerns:

  • Impaired glucose metabolism and elevated blood glucose with prolonged use
  • Potential tachyphylaxis (reduced response) with continuous daily dosing
  • Theoretical promotion of existing malignancies through elevated GH/IGF-1 (applies to all GH-elevating compounds)

Side effect incidence tends to be lower than with exogenous hGH because GHRP-2 stimulates endogenous GH synthesis within physiological regulatory limits. The eight-month pediatric study by Mericq et al. reported no side effects or toxicities at any dose level tested.

Frequently Asked Questions

Common side effects include increased appetite, flushing, transient drowsiness, water retention, and mild elevations in cortisol and prolactin. These effects are generally dose-dependent and less pronounced than with GHRP-6. Serious adverse events are rare in published clinical data.

By peak GH output, GHRP-2 is generally considered the most potent of the traditional GHRPs (GHRP-1, GHRP-2, GHRP-6, hexarelin). A study by Arvat et al. (1997) showed GHRP-2 produced GH responses exceeding those of maximal-dose GHRH when administered intravenously. However, hexarelin is comparable in potency with a slightly different side effect profile.

GHRP-2 is used off-label in anti-aging protocols to restore more youthful GH pulsatility. Elevated GH and IGF-1 levels are associated with improved skin quality, body composition, sleep, and recovery. Long-term safety data for this specific application is limited, and it remains unapproved for this use.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891.
  2. Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2355-2360.
  3. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614.
  6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  7. Pihoker C, et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology & Metabolism. 1995;80(10):2987-2992.
  8. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D. Drugs in R&D. 2004;5(4):236-239.
  9. Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27.
  10. Thomas A, et al. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by LC-MS/MS. Rapid Communications in Mass Spectrometry. 2010;24(11):1549-1557.
  11. World Anti-Doping Agency. The 2026 Prohibited List International Standard.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”